Analysis Date: March 11, 2026
Prepared by: Ada Cockpit
Coverage: Horizon (Amgen) portfolio — In-Market Finder opportunities
Horizon Therapeutics, acquired by Amgen in October 2023 for $27.8B, operates a portfolio of rare disease and specialty therapeutics generating $4.5B in rare disease revenue (2024). This analysis evaluates Patient Finder (PF) suitability across 6 marketed drugs.
Total Tier 1 Opportunity (TEPEZZA + KRYSTEXXA at 5% capture): $52.9M annually
All Tiers Combined (5% capture): $57.5M annually
| Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity (5% Capture) | Key Insight |
|---|---|---|---|---|---|
| TEPEZZA Thyroid Eye Disease |
1 | 9/10 | 7,534 | $31.2M/year | 58% misdiagnosis, 9-month delay, blockbuster |
| KRYSTEXXA Chronic Refractory Gout |
1 | 8/10 | 71,581 | $21.7M/year | URGENT — Competition 2025, largest pool |
| UPLIZNA NMOSD |
2 | 6/10 | 3,871 | $4.6M/year | 44% MS misdiagnosis, moderate fit |
| RAVICTI Urea Cycle Disorders |
NO | 3/10 | <500 | Not viable | Ultra-rare, generic erosion, newborn screening |
| PROCYSBI Nephropathic Cystinosis |
NO | 2/10 | <100 | Not viable | Ultra-rare (~600 total US patients), early diagnosis |
| ACTIMMUNE CGD, Osteopetrosis |
NO | 2/10 | <100 | Not viable | Ultra-rare, severe early presentation |
Indication: Thyroid Eye Disease (TED) / Graves' Ophthalmopathy
FDA Approval: January 2020 (first and only approved therapy)
2024 Revenue: $1.9 billion
| Region | Total Moderate-Severe TED | Undiagnosed (35%) | Drug-Addressable | PF Fee/Patient | Total Opportunity |
|---|---|---|---|---|---|
| USA | 53,600 | 18,760 | 7,534 | $23,375 | $176M |
| DACH | 29,600 | 10,360 | 4,163 | $18,700 | $78M |
| ROW | 150,000 | 52,500 | 21,114 | $17,531 | $370M |
| GLOBAL | 233,200 | 81,620 | 32,811 | — | $624M |
| Capture Rate | Patients Found (Global) | Annual PF Revenue |
|---|---|---|
| 1% | 328 | $6.24M/year |
| 5% | 1,641 | $31.2M/year |
Ada Surface Ability: 8/10 — Eye bulging + double vision + thyroid symptoms = strong distinctive pattern
Company Motivation: 9/10 — Blockbuster facing pipeline competition, high urgency
Overall Fit: 9/10
"TEPEZZA patients wait 9 months for diagnosis and 58% are initially misdiagnosed as conjunctivitis or dry eye. With pipeline competitors launching in 2-3 years, now is the critical window to expand your diagnosed patient base. Ada's symptom assessment can identify the distinctive TED pattern (eye bulging + thyroid symptoms) and route patients to ophthalmologists before your market fragments. At 5% capture, Patient Finder delivers $31M annually while protecting your $1.9B franchise."
Indication: Chronic Refractory Gout (CRG)
FDA Approval: September 2010
2024 Revenue: $1.2 billion
| Region | Total CRG Patients | Undiagnosed (30%) | Drug-Addressable | PF Fee/Patient | Total Opportunity |
|---|---|---|---|---|---|
| USA | 598,000 | 179,400 | 71,581 | $4,900 | $351M |
| DACH | 39,423 | 11,827 | 4,721 | $3,675 | $17M |
| ROW | 150,000 | 45,000 | 17,955 | $3,675 | $66M |
| GLOBAL | 787,423 | 236,227 | 94,257 | — | $434M |
| Capture Rate | Patients Found (Global) | Annual PF Revenue |
|---|---|---|
| 1% | 943 | $4.34M/year |
| 5% | 4,713 | $21.7M/year |
Ada Surface Ability: 6/10 — Can capture recurrent gout + treatment failure pattern, requires medication history
Company Motivation: 10/10 — URGENT competitive pressure
Overall Fit: 8/10
"SEL-212 launches in 2025, threatening your $1.2B KRYSTEXXA franchise. Gout patients face diagnostic delays due to limited joint aspiration access, and refractory cases often suffer for years before proper diagnosis. The next 12-18 months are critical to lock in patients before your market fragments. Ada can identify the pattern: recurrent gout + treatment failure + elevated uric acid symptoms. At 5% capture, Patient Finder delivers $21.7M annually while protecting market share during the competitive transition."
ACTION: Approach Amgen IMMEDIATELY — This is the most time-sensitive opportunity in the entire Horizon portfolio.
Indication: Neuromyelitis Optica Spectrum Disorder (NMOSD)
FDA Approval: June 2020 (expanded to myasthenia gravis 2025)
2024 Revenue: $379 million
| Region | AQP4+ NMOSD | Undiagnosed (32.5%) | Drug-Addressable | PF Fee/Patient | Total Opportunity |
|---|---|---|---|---|---|
| USA | 18,438 | 5,992 | 3,871 | $20,000 | $77M |
| DACH | 880 | 286 | 185 | $15,000 | $2.8M |
| ROW | 3,500 | 1,138 | 736 | $15,000 | $11M |
| GLOBAL | 22,818 | 7,416 | 4,792 | — | $90.8M |
| Capture Rate | Patients Found (Global) | Annual PF Revenue |
|---|---|---|
| 1% | 48 | $0.92M/year |
| 5% | 240 | $4.6M/year |
Ada Surface Ability: 5/10 — Moderate fit; symptoms overlap with MS, requires clinical sophistication
Company Motivation: 6/10 — Moderate interest, not urgent
Overall Fit: 6/10
"44% of NMOSD patients are initially misdiagnosed as multiple sclerosis, delaying appropriate treatment by an average of 21 months. UPLIZNA's $379M franchise could grow by improving differential diagnosis. Ada's symptom assessment can flag the distinctive NMOSD pattern - severe optic neuritis + transverse myelitis + brainstem symptoms - and route to neurology with NMOSD suspicion rather than generic MS. At 5% capture, Patient Finder delivers $4.6M annually while supporting your recent myasthenia gravis expansion."
ACTION: Pursue if TEPEZZA/KRYSTEXXA deals close. Smaller opportunity but viable.
Indication: Urea Cycle Disorders
Revenue: $758M (2024 ultra-rare group total — RAVICTI + PROCYSBI + ACTIMMUNE bundled)
Key Issue: Generic competition causing 27% revenue decline (Q4 2025)
Indication: Nephropathic Cystinosis
Total US Patient Population: Only 500-600 diagnosed cases
New Cases: ~15 per year
Indications: Chronic Granulomatous Disease (CGD) / Severe Malignant Osteopetrosis
New Cases Annually: CGD ~20/year, Osteopetrosis 8-40/year (US)
Timeline: SEL-212 launches 2025 — critical 12-18 month window
Action: Approach Amgen IMMEDIATELY with competitive pressure positioning
Value Proposition: Lock in patients before market fragmentation, protect $1.2B franchise
Feasibility: HIGH — Company extremely motivated (10/10), large addressable pool (71,581 US), proven diagnostic barriers
Expected Revenue (5% capture): $21.7M annually
Timeline: Pipeline competitors (VRDN-001, batoclimab) expected 2026-2027
Action: Approach within 6 months, emphasize diagnostic delay (9 months, 58% misdiagnosis)
Value Proposition: Expand diagnosed pool before monopoly ends, protect blockbuster
Feasibility: HIGH — Strong motivation (9/10), excellent clinical fit (8/10), largest opportunity ($31.2M at 5%)
Expected Revenue (5% capture): $31.2M annually
Timeline: No urgency, stable competitive market
Action: Approach if TEPEZZA/KRYSTEXXA deals close, emphasize MS misdiagnosis differential
Value Proposition: Improve NMOSD vs MS diagnosis, support MG expansion
Feasibility: MODERATE — Smaller market, moderate clinical fit (5/10), less urgent company need (6/10)
Expected Revenue (5% capture): $4.6M annually
RAVICTI, PROCYSBI, ACTIMMUNE: Ultra-rare diseases with minimal addressable populations. Not economically viable for Patient Finder. Do not pursue.
| Scenario | Drugs Included | Total Annual PF Revenue (5% Capture) |
|---|---|---|
| Tier 1 Only | TEPEZZA + KRYSTEXXA | $52.9M/year |
| All Tiers | TEPEZZA + KRYSTEXXA + UPLIZNA | $57.5M/year |
| Best Case (1 deal) | KRYSTEXXA only (most urgent) | $21.7M/year + franchise protection |